Investor Overview

Overview

Tricida, Inc. , is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.

Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases.

SEC Filings

Filing date Description Form View

Report of unscheduled material events or corporate event

8-K View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

A statement of beneficial ownership of common stock by certain persons

SC 13G View HTML

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Report of unscheduled material events or corporate event

8-K View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

An amendment to the SC 13G filing

SC 13G/A View HTML

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.